Package Insert: Information for the Patient
Senshio 60 mg Film-Coated Tablets
ospemifeno
Read this package insert carefully before starting to take this medication, as it contains important information for you.
Senshio contains the active ingredient ospemifeno.
Ospemifeno belongs to a group of medications that do not contain hormones, known as selective estrogen receptor modulators (SERMs).
Senshio is usedto treat women with moderate to severe postmenopausal symptoms inside and outside the vagina, such as itching, dryness, burning, or pain during sex (dyspareunia). This is known as vulvar and vaginal atrophy. It is caused by a reduction in the levels of the female hormone estrogen in the body. When this occurs, the vaginal walls become thinner. This occurs naturally after menopause (postmenopause).
Senshio actsin a similar way to some of the beneficial effects of estrogen, helping to improve these symptoms and the underlying causes of vulvar and vaginal atrophy.
Do not take Senshio
|
Warnings and precautions
Once you start taking Senshio, you should see your doctor for regular check-ups (at least once a year). During these check-ups, consult with your doctor about the benefits and risks associated with continuing to take Senshio.
Consult your doctor or pharmacist before starting to take Senshioif any of the following situations apply to you:
During Senshio treatment:
Children and adolescents
Do not give this medication to children or adolescents. This medication is intended only for postmenopausal women.
Other medications and Senshio
Inform your doctor or pharmacist if you are taking, have taken recently or may need to take any other medication.
Do not take Senshio with any of the following medications:
Consult your doctor before taking Senshiowith:
Pregnancy, breastfeeding and fertility
Senshio is intended for exclusive use in postmenopausal women. Women who are pregnant, may still be able to have a child or are breastfeeding should not take it. This is because there is no data available on the use of Senshio in pregnant women or premenopausal women or those breastfeeding.
If you become pregnant while taking Senshio, inform your doctor immediately;you should stop treatment immediately.
Driving and operating machinery
Senshio has no known influence or its influence on the ability to drive and operate machinery is very small.
Senshio contains lactose
If your doctor has told you that you have an intolerance to certain sugars, consult with him before taking this medication.
Senshio contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially "sodium-free".
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
The recommended dose is a tablet taken orally at the same time every day. Senshio should be taken with food. The tablets should be swallowed whole with food.
Senshio should be taken every day until your doctor tells you otherwise.
Patients with liver disease
This medication is not recommended if your liver function is severely reduced.
If you take more Senshio than you should
If you take more tablets than you should, inform your doctor or pharmacist.
If you forget to take Senshio
If you forget to take a tablet, you should take the missed tablet (with food) as soon as you remember on the same day. Do not take two tablets on the same day to make up for the missed tablet.
If you interrupt treatment with Senshio
You will not benefit from the effects of Senshio if you interrupt treatment with the medication without consulting your doctor. Your doctor will explain the effects of interrupting treatment and will also discuss other treatment possibilities with you.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication may produce adverse effects, although not all people may experience them.
Frequent Adverse Effects(may affect up to 1 in 10 people):
Less Frequent Adverse Effects(may affect up to 1 in 100 people):
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicinal Products for Human Use: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information about the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box and the blister pack after “CAD”. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the packaging and medications that you no longer need. In this way, you will help protect the environment.
Composition of Senshio
Tablet core:colloidal silicon dioxide (E 551), magnesium stearate (E 578), mannitol (E 421), microcrystalline cellulose (E 460), povidone (E 1201), pregelatinized cornstarch and sodium starch glycolate (type A).
Film coating:hypromellose (E 464), lactose monohydrate, titanium dioxide (E 171), triacetin (E 1518) and polyethylene glycol (E 1521).
Appearance of the product and contents of the package
Senshio tablets are oval, biconvex, white or off-white film-coated tablets (approximately 12 mm in length and 6.45 mm in width), engraved with “60” on one side.
They are packaged in blisters and are available in package sizes of 7, 28 or 84 film-coated tablets.
Only some package sizes may be commercially available.
Marketing Authorization Holder
Shionogi B.V.
Herengracht 464
1017CA Amsterdam
Netherlands
Responsible for manufacturing
Shionogi B.V.
Herengracht 464
1017CA Amsterdam
Netherlands
For more information about this medicine, please contact the local representative of the marketing authorization holder:
AT, BE, BG, CY, CZ, DK, EE, IE, EL, FI, FR, HR, HU, IE, IS, LT, LU, LV, MT, NL, NO, PL, RO, SE, SI, SK Shionogi B.V. Tel/Tel./Te?./Tlf/Tél/Puh/Sími/Τηλ: +31 (0)20 491 7439 | DE Shionogi GmbH Tel: +49 (0) 30 2062980 66 |
ES Shionogi SLU Tel: +34911239 258 PT Lifewell Pharmaceutical & Healthcare, Lda. Tel:+351215810558 UK (NI) Shionogi B.V. Tel +44 (0) 2891248945 | IT Shionogi Srl Tel:+39 06 94 805 118 FR Shionogi SAS Tel: +33 (0) 186655806 |
Last date of revision of this leaflet: 01/2023
Other sources of information
Further information on this medicine is available on the website of the European Medicines Agency:http://www.ema.europa.eu.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.